299 related articles for article (PubMed ID: 28605510)
1. Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.
Kieran MW; Chisholm J; Casanova M; Brandes AA; Aerts I; Bouffet E; Bailey S; Leary S; MacDonald TJ; Mechinaud F; Cohen KJ; Riccardi R; Mason W; Hargrave D; Kalambakas S; Deshpande P; Tai F; Hurh E; Geoerger B
Neuro Oncol; 2017 Oct; 19(11):1542-1552. PubMed ID: 28605510
[TBL] [Abstract][Full Text] [Related]
2. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors.
Rodon J; Tawbi HA; Thomas AL; Stoller RG; Turtschi CP; Baselga J; Sarantopoulos J; Mahalingam D; Shou Y; Moles MA; Yang L; Granvil C; Hurh E; Rose KL; Amakye DD; Dummer R; Mita AC
Clin Cancer Res; 2014 Apr; 20(7):1900-9. PubMed ID: 24523439
[TBL] [Abstract][Full Text] [Related]
3. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
4. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.
Shou Y; Robinson DM; Amakye DD; Rose KL; Cho YJ; Ligon KL; Sharp T; Haider AS; Bandaru R; Ando Y; Geoerger B; Doz F; Ashley DM; Hargrave DR; Casanova M; Tawbi HA; Rodon J; Thomas AL; Mita AC; MacDonald TJ; Kieran MW
Clin Cancer Res; 2015 Feb; 21(3):585-93. PubMed ID: 25473003
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors.
Stathis A; Hess D; von Moos R; Homicsko K; Griguolo G; Joerger M; Mark M; Ackermann CJ; Allegrini S; Catapano CV; Xyrafas A; Enoiu M; Berardi S; Gargiulo P; Sessa C;
Invest New Drugs; 2017 Dec; 35(6):766-772. PubMed ID: 28317088
[TBL] [Abstract][Full Text] [Related]
6. A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.
Ruiz-Borrego M; Jimenez B; Antolín S; García-Saenz JA; Corral J; Jerez Y; Trigo J; Urruticoechea A; Colom H; Gonzalo N; Muñoz C; Benito S; Caballero R; Bezares S; Carrasco E; Rojo F; Martín M
Invest New Drugs; 2019 Feb; 37(1):98-108. PubMed ID: 29948356
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer.
Pietanza MC; Litvak AM; Varghese AM; Krug LM; Fleisher M; Teitcher JB; Holodny AI; Sima CS; Woo KM; Ng KK; Won HH; Berger MF; Kris MG; Rudin CM
Lung Cancer; 2016 Sep; 99():23-30. PubMed ID: 27565909
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B;
Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663
[TBL] [Abstract][Full Text] [Related]
9. Exposure-Response Analysis of Sonidegib (LDE225), an Oral Inhibitor of the Hedgehog Signaling Pathway, for Effectiveness and Safety in Patients With Advanced Solid Tumors.
Zhou J; Quinlan M; Hurh E; Sellami D
J Clin Pharmacol; 2016 Nov; 56(11):1406-1415. PubMed ID: 27095306
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study.
Gajjar A; Stewart CF; Ellison DW; Kaste S; Kun LE; Packer RJ; Goldman S; Chintagumpala M; Wallace D; Takebe N; Boyett JM; Gilbertson RJ; Curran T
Clin Cancer Res; 2013 Nov; 19(22):6305-12. PubMed ID: 24077351
[TBL] [Abstract][Full Text] [Related]
11. Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors.
Quinlan M; Zhou J; Hurh E; Sellami D
Eur J Clin Pharmacol; 2016 Dec; 72(12):1427-1432. PubMed ID: 27663457
[TBL] [Abstract][Full Text] [Related]
12. Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors.
Minami H; Ando Y; Ma BB; Hsiang Lee J; Momota H; Fujiwara Y; Li L; Fukino K; Ito K; Tajima T; Mori A; Lin CC
Cancer Sci; 2016 Oct; 107(10):1477-1483. PubMed ID: 27467121
[TBL] [Abstract][Full Text] [Related]
13. Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia.
Irvine DA; Zhang B; Kinstrie R; Tarafdar A; Morrison H; Campbell VL; Moka HA; Ho Y; Nixon C; Manley PW; Wheadon H; Goodlad JR; Holyoake TL; Bhatia R; Copland M
Sci Rep; 2016 May; 6():25476. PubMed ID: 27157927
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors.
Goel V; Hurh E; Stein A; Nedelman J; Zhou J; Chiparus O; Huang PH; Gogov S; Sellami D
Cancer Chemother Pharmacol; 2016 Apr; 77(4):745-55. PubMed ID: 26898300
[TBL] [Abstract][Full Text] [Related]
15. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
[TBL] [Abstract][Full Text] [Related]
16. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.
Robinson GW; Orr BA; Wu G; Gururangan S; Lin T; Qaddoumi I; Packer RJ; Goldman S; Prados MD; Desjardins A; Chintagumpala M; Takebe N; Kaste SC; Rusch M; Allen SJ; Onar-Thomas A; Stewart CF; Fouladi M; Boyett JM; Gilbertson RJ; Curran T; Ellison DW; Gajjar A
J Clin Oncol; 2015 Aug; 33(24):2646-54. PubMed ID: 26169613
[TBL] [Abstract][Full Text] [Related]
17. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
Danial C; Sarin KY; Oro AE; Chang AL
Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E1 Inhibits
Wu F; Zhang C; Zhao C; Wu H; Teng Z; Jiang T; Wang Y
Cancer Res; 2020 Jul; 80(13):2818-2832. PubMed ID: 32371475
[TBL] [Abstract][Full Text] [Related]
19. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.
Migden MR; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kudchadkar R; Trefzer U; Gogov S; Pallaud C; Yi T; Mone M; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Chang AL; Cornélis F; Lear JT; Sellami D; Dummer R
Lancet Oncol; 2015 Jun; 16(6):716-28. PubMed ID: 25981810
[TBL] [Abstract][Full Text] [Related]
20. Identification of pseudolaric acid B as a novel Hedgehog pathway inhibitor in medulloblastoma.
Wei SF; He DH; Zhang SB; Lu Y; Ye X; Fan XZ; Wang H; Wang Q; Liu YQ
Biochem Pharmacol; 2021 Aug; 190():114593. PubMed ID: 33964282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
